 |
 |
|
|
|
| Ambrisentan |
 |
| (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid |
 |
| 177036-94-1 |
 |
| Ambrisentan ) is an orally-active endothelin-A receptor antagonist, developed by Abbott for the treatment of pulmonary arterial hypertension (PAH), chronic heart failure and chronic renal failure. |
 |
Description: Yellowish to white crystalline powder
Loss on drying NMT 1.0%
Residue on ignition NMT 0.2%
Related substances NMT 1.0% (HPLC)
Assay: 98.0--102.0% (HPLC) |
| Industrial field |
pharmaceutical |
|
|
 |
 |
|
IFFECT CHEMPHAR CO., LTD
|
| Phone |
+86-755-8376-1610 |
| Fax |
+86-755-8327-9595 |
| Homepage |
- |
| E-mail |
sales3@iffchem.com.cn
|
| Address |
3804-3805, International Science & Technology Building,
No.3007 Shennan Road, Futian Dis. Shenzhen 518033, P.R. China |
|
 |
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
|
|
|
|
